

FOR IMMEDIATE RELEASE

**For more information, contact
Jill Shoemaker
Vice President of Investor Relations
(970) 231-3243
jshoemaker@st-renatus.com**

ST. RENATUS AWARDED FEDERAL GRANT

Start-up company receives more than \$240,000 for its dental anesthetic technology

Fort Collins, Colo. – November 8, 2010 – St. Renatus, LLC, the northern Colorado start-up company, dedicated to market the world’s first needle-free dental anesthetic, announced today it was awarded a \$244,479.25 grant from the Qualifying Therapeutic Discovery Project (QTDP) Program. This program is sponsored by the Patient Protection and Affordable Care Act (Public Law 111-148), the IRS and the Department of Health and Human Services (HHS).

The program was established to recognize and award small (fewer than 250 employees) bioscience companies who produce new therapies, address medical needs, add additional jobs, reduce health care costs and/or develop cures for cancer. St. Renatus applied for the grant in July with hopes that its nasal mist product would qualify in the area of oral pain therapy. According to the HHS press release, the allocated \$1 billion in tax credit and grants was awarded amongst 2,923 companies throughout the United States.

“This is extremely good news for our company,” said Steven T. Merrick, St. Renatus’ CEO. “We are fortunate there are programs, like the Qualifying Therapeutic Discovery Project, which provide additional resources that help us during our final phase of drug testing.”

The company will use the therapeutic grant to fund clinical studies and ongoing operations. St. Renatus is currently undergoing U.S. Food and Drug Administration (FDA) clinical testing for its nasal mist anesthetic, which is administered through the nasal cavity and suitable for use in procedures involving most of the upper teeth. The company anticipates beginning FDA Phase 3 clinical trials in early 2011. Upon completion of the trials, it will then submit the New Drug Application (NDA) for FDA approval.

- ### -

About St. Renatus

St. Renatus, LLC was founded to commercialize the world’s first needle-free dental anesthetic suitable for use in procedures involving most of the upper teeth. By bringing this product to market, St. Renatus aims to create a better experience for dentists and qualifying patients by using an accurate and sophisticated method to anesthetize the upper teeth without the risk and pain of a needle. For more information on St. Renatus, visit www.st-renatus.com or call 970.282.0156.